Affibody Ab

Genentech, Inc.

General Electric Company

Active Biotech Ab

Kabigen Ab

Ge Healthcare Bio-sciences Ab

Pharmacia & Upjohn Aktiebolag

Active Biotech Ag

Lars B Abrahmsen

Elin Gunneriusson

James A Wells

John P Burnier

Caroline Ekblad

Rong Zhang

Faisal Ahmed Syud

Joachim Feldwisch

Christofer Lendel

Fredrik Frejd

Brian Duh-Lan Lee

Nina Herne

Peter Brian Iveson

Paul Schaffer

Mikael Dohlsten

Bjorn Nilsson

Terje Kalland

Tove Simonsson

Mathias Uhlen

Malin Lindborg

Torbjörn Gräslund

Johan Seijsing

Per Bjork

Tomas Moks

David Y Jackson

Göran Forsberg

Cesare Sirtori

Mats Lake

Erik Holmgren

John Löfblom

Tove Eriksson

Peter Lind

Per Antonsson

Joanna Chmielewska

Guido Franceschini

Johan Hansson

John Löblom

Peter Lando

Morten Soegaard

David T Jackson

Andreas Jonsson

John Lofblom

Torbjorn Graslund

Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.

HER2 binders

Imaging agents comprising an isolated polypeptide conjugated with a radionuclide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.

The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EXXXAXXEIRWLPNL XXXQRXAFIXXLXX. The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.

Polypeptides

The present disclosure relates to a class of engineered polypeptides having a binding affinity for albumin. It also relates to new methods and uses that exploit binding by these and other compounds to albumin in different contexts, some of which have significance for treatment or diagnosis of disease in mammals including humans.

The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EXXXAXXEIRWLPNL XXXQRXAFIXXLXX(SEQ ID NO: 1075). The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.

An immunoglobulin G Fc region binding polypeptide is provided, consisting of an amino acid sequence selected from i) a variant of Protein A domain or Protein Z and ii) an amino acid sequence which has at least 95% identity thereto. Also provided are methods for producing the polypeptide, compositions comprising the polypeptide, polynucleotides encoding the polypeptide, multimers of the polypeptide, and methods of using the polypeptide.

Immunoglobulin G Fc region binding polypeptide

A method for the treatment of a disease in a mammal by administering a therapeutically effective amount of a conjugate comprising a biospecific affinity counterpart and a peptide, wherein the peptide contains an amino acid sequence that is derived from staphylococcal enterotoxin A, binds to a V&#x3b2; of a T cell receptor, and has a D227A mutation so that the peptide has a modified ability to bind to MHC class II antigens.

Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate

A conjugate between a target-seeking moiety and a modified superantigen, characterized in that the superantigen is a wild-type superantigen (SA I) in which an amino acid residue in a superantigen region (region I) determining binding to TCR, preferably TCRV&#x3b2;, and T cell activation have been replaced by another amino acid residue while retaining the ability to activate a subset of T cells. In preferred embodiment the modified superantigen is a chimer between at least two wild-type superantigens (SA I, SA II etc) characterized in that one or more amino acid residues in a region determining binding to TCR and T cell activation have been interchanged between various wild-type superantigens. A therapeutic method making use of modified/chimeric superantigens as defined in the preceding paragraphs. An antibody preparation in which the cysteine residues that provide for interchain disulfide bonds have been mutated so as to forbid interchain disulfide bridges, preferably to serine residues, for use as pharmaceutical.

Modified Chimeric superantigens and their use

A method for inactivating target cells in the presence of T cells by bringing the two types of cells in contact with a superantigen (SAG) in the presence of an immune modulator, characterized in that at least one of the superantigen and the immune modulator is in the form of a conjugate between a 'free' superantigen (Sag) and a moiety targeting the conjugate to the target cells. A superantigen conjugate complying with the formula (1) (T)(Sag)(IM); a) T is a targeting moiety, Sag corresponds to a free superantigen, IM is an immune modulator that is not a superantigen and T, Sag and IM are linked together via organic linkers B; b) x, y and z are integers that typically are selected among 0-10 and represent the number of moieties T, Sag and IM, respectively, in a given conjugate molecule, with the provision that y&#x3e;0 and also one or both of x and z&#x3e;0. The superantigen conjugate is preferably a triple fusion protein. A targeted immune modulator, characterized in that it is a conjugate between a targeting moiety (T&#x2033;') and a modified immune modulator (IM&#x2033;&#x2032;). The conjugate complies with a formula analogous to formula (1) except for the imperative presence of the modified immune modulator. A superantigen moiety may be present. A DNA molecule encoding a superantigen and an immune modulator.

Cytolysis of target cells by superantigen conjugates inducing T-cell activation

Dimer of molecular variant of apolipoprotein and processes for the

The invention relates to serine protease variants derived from precursor serine proteases via recombinant and/or chemical methods to form protease variants having improved peptide ligase activity. The invention also includes novel ligation substrates which in combination with the serine protease variants and a second ligation substrate are capable of forming a ligation product. The invention also relates to methods for forming such ligation products and the products formed thereby.

Serine protease variants having peptide ligase activity

Methods of use of serine protease variants having peptide ligase activity

Growing community of inventors

Stockholm, Sweden

Lars B Abrahmsen